Pityriasis Rosea: Herald Patch, Christmas Tree Pattern, and Differential Diagnosis
Executive Summary
S1 · Pathogenesis and HHV-6/HHV-7 Reactivation
Pityriasis rosea (PR) was historically considered idiopathic, but converging evidence now strongly supports endogenous reactivation of human herpesvirus 6 (HHV-6) and HHV-7 as the principal cause. Both viruses establish lifelong latency in T lymphocytes, monocytes/macrophages, and salivary glands following primary infection (HHV-6 causes roseola infantum in early childhood; HHV-7 causes a similar exanthem). Reactivation in adolescence or young adulthood, possibly triggered by stress, fatigue, or immune perturbation, leads to systemic viremia and a cell-mediated immune response that produces the cutaneous eruption.
Viral evidence
- Detection in plasma: HHV-6 and HHV-7 DNA detected by PCR in plasma of 40–80% of acute PR patients vs <5% of controls, with viral loads peaking at the herald patch stage and declining as the rash resolves.
- Lesional skin: HHV-6/HHV-7 DNA found in fresh PR plaques on PCR and immunohistochemistry; ultrastructural studies show herpesvirus-like particles in keratinocytes and dermal mononuclear cells.
- mRNA expression: Detection of viral mRNA (a marker of active replication, not just latent DNA) confirms reactivation rather than passive presence.
- HHV-7 may be primary trigger: HHV-7 reactivation often precedes HHV-6 reactivation in PR patients, suggesting HHV-7 may be the principal initiating virus with HHV-6 reactivating secondarily.
Epidemiology and seasonal pattern
Annual incidence is approximately 170 per 100,000, with peak occurrence between ages 10 and 35 years; rare under age 2 or over 60 years. There is a slight female predominance (1.5:1). Incidence shows seasonal clustering with peaks in spring and autumn in temperate climates, and small clusters within households or military barracks have been reported, although person-to-person transmission has not been definitively demonstrated. Lifetime recurrence rate is only 2–3%.
Drug-induced PR-like eruptions
Several medications can cause a PR-like eruption that is generally more confluent, more pruritic, more violaceous, and lacks a herald patch. Important drug triggers include:
- ACE inhibitors (captopril, enalapril)
- Beta-blockers (metoprolol, atenolol)
- Antimicrobials: metronidazole, terbinafine, isotretinoin
- NSAIDs: aspirin, naproxen, ketotifen
- Biologics: imatinib, adalimumab, infliximab, rituximab, nivolumab, pembrolizumab
- Vaccines: BCG, smallpox, COVID-19 mRNA vaccines, hepatitis B, influenza, HPV
- Heavy metals: gold, bismuth, arsenic
- Other: hydrochlorothiazide, omeprazole, clozapine, lithium
Drug-induced PR typically resolves with discontinuation of the offending agent; resolution may take longer (8–12 weeks) than classic PR.
S2 · Clinical Presentation and Variants
Prodrome
A mild prodrome of malaise, low-grade fever, headache, arthralgia, lymphadenopathy, or upper respiratory symptoms is reported in 5–20% of patients in the days preceding the herald patch — consistent with the underlying viremia. Most patients are otherwise well at presentation.
Herald patch (primary medallion)
In 50–90% of cases, a solitary herald patch precedes the generalized eruption by 5–15 days (median 1–2 weeks). Features:
- Size: 2–10 cm (typically 3–5 cm)
- Shape: oval to round, well-demarcated
- Color: salmon-pink in light skin; hyperpigmented brown or violaceous in darker skin
- Surface: peripheral fine “collarette” of scale at the inner edge of the lesion (the scale faces the center, like an inverted shoreline)
- Location: trunk (most common — chest, abdomen, back), neck, or proximal upper extremities; rarely face or distal limbs
- Symptoms: mildly pruritic or asymptomatic
The herald patch is often misdiagnosed as tinea corporis (and treated futilely with topical antifungals) or nummular eczema before the generalized eruption clarifies the diagnosis.
Secondary eruption — “Christmas tree” pattern
5–15 days after the herald patch, multiple smaller secondary lesions erupt in successive crops over 2–10 days, peaking at 2 weeks:
- Size: 5–15 mm (typically 1 cm); smaller than the herald patch
- Shape: oval, with the long axis aligned along Langer lines (lines of skin cleavage)
- Color: salmon-pink to pinkish-brown
- Surface: collarette scale at the inner edge of each lesion
- Distribution: trunk and proximal extremities; the long axes parallel to ribs and skin folds creates the characteristic “Christmas tree” or “fir tree” appearance on the back when the lesions are viewed against the spine
- Spared areas: face, scalp, palms, soles, and distal extremities (in the classic form)
- Symptoms: pruritus in 50–75%, mild to moderate; severe pruritus is uncommon
Atypical variants (~20% of cases)
| Variant | Distinguishing Features | Clinical Pearl |
|---|---|---|
| Inverse PR | Lesions concentrated in flexures (axillae, groin, antecubital fossae), spares trunk | More common in children and dark-skinned patients; may mimic intertrigo or seborrheic dermatitis |
| Acral PR | Predominantly on palms, soles, distal extremities | Especially difficult to distinguish from secondary syphilis — mandatory RPR |
| Vesicular PR | Vesicles or pustules on plaques | More common in children and dark-skinned patients; may mimic varicella or scabies |
| Purpuric/hemorrhagic PR | Petechiae and purpura within plaques | Usually self-limited but warrants exclusion of vasculitis or thrombocytopenia |
| Urticarial PR | Wheal-like edematous lesions | Mimics chronic urticaria |
| Giant PR (PR gigantea of Darier) | Few but very large (>5 cm) plaques | Rare; typically resolves like classic PR |
| Pityriasis rosea irritata | Intensely pruritic, lichenified, often after vigorous scrubbing or sweating | Can be confused with eczema; emollients and topical steroids help |
| Persistent PR | Eruption lasting >12 weeks | Reconsider diagnosis; rule out drug-induced PR, syphilis, mycosis fungoides |
| Recurrent PR | Second episode within 6 months — rare (2–3%) | Consider drug-induced PR or atypical mimic |
S3 · Diagnostic Approach
Clinical diagnosis
PR is a clinical diagnosis based on the characteristic herald patch followed by a Christmas-tree distribution of oval salmon-pink plaques with collarette scale. No laboratory test confirms the diagnosis directly. The Chuh diagnostic criteria are commonly applied:
| Required Features | Excluding Features |
|---|---|
| 1. Discrete circular or oval lesions 2. Scaling on most lesions 3. Peripheral collarette scaling on at least 2 lesions | 1. Multiple small vesicles in the center of two or more lesions 2. Two or more lesions on palms or soles 3. Clinical or serological evidence of syphilis |
Mandatory laboratory evaluation
Optional/conditional tests
- HIV test — recommended in sexually active patients due to atypical PR-like presentations in HIV seroconversion and overlap with secondary syphilis risk.
- KOH preparation — to exclude tinea corporis when herald patch is solitary or if scalp/intertriginous involvement.
- CBC, ESR, CRP — generally normal or mildly elevated; not routinely needed but reasonable in atypical or persistent cases.
- Skin biopsy — reserved for atypical, persistent (>12 weeks), or refractory cases; histology shows nonspecific features (focal parakeratosis, mild spongiosis, dyskeratotic keratinocytes, perivascular lymphocytic infiltrate, extravasated erythrocytes), enough to exclude mycosis fungoides, lichen planus, and syphilis but not diagnostic alone.
- HHV-6/HHV-7 PCR — research/academic use only; not clinically required.
When to consider alternative diagnoses
- Palm/sole involvement → think syphilis
- Mucosal lesions → think syphilis, lichen planus, erythema multiforme
- Fever, lymphadenopathy → think syphilis, viral exanthem, drug reaction
- Persistent >12 weeks → think drug-induced PR, mycosis fungoides, parapsoriasis, secondary syphilis
- Vesicles/pustules → think varicella, hand-foot-mouth, scabies (especially if pruritic burrows)
- Annular configuration with central clearing → think tinea corporis (KOH +)
S4 · Differential Diagnosis
| Condition | Distinguishing Features | Confirmatory Test |
|---|---|---|
| Secondary syphilis | Palm/sole involvement, copper-colored papules, lymphadenopathy, mucous patches, condyloma lata, alopecia, constitutional symptoms; sexual exposure history | RPR/VDRL with treponemal confirmation |
| Tinea corporis | Single or few lesions with raised active border and central clearing; scale at the outer edge (not inner); less symmetric distribution | KOH prep — fungal hyphae |
| Nummular eczema | Coin-shaped, intensely pruritic, lichenified, oozing or crusted; often on extremities; chronic and recurrent | Clinical, biopsy if uncertain |
| Guttate psoriasis | Small drop-like papules with thicker silvery (not collarette) scale; often follows streptococcal pharyngitis (2–3 weeks); scalp/nail involvement | Clinical + ASO titer; biopsy if uncertain |
| Drug eruption (PR-like) | No herald patch; more confluent, violaceous, more pruritic; recent new medication or vaccine | Medication history; resolves with drug withdrawal |
| Viral exanthem (HHV-6/HHV-7 primary, EBV, parvovirus B19) | Acute morbilliform/maculopapular eruption with fever; not oval/collarette; younger children | Viral serology if needed |
| Mycosis fungoides (early-stage CTCL) | Persistent, asymmetric patches and plaques with poikiloderma; sun-protected areas; chronic course | Skin biopsy — atypical lymphocytes, epidermotropism |
| Pityriasis lichenoides chronica (PLC) | Recurrent crops of brownish papules with mica-like central scale; chronic course (months to years) | Biopsy |
| Lichen planus | Polygonal, violaceous, flat-topped papules with Wickham striae; wrist flexors, ankles, lower back; mucosal involvement common | Clinical + biopsy |
| Seborrheic dermatitis | Greasy yellow scale; scalp, eyebrows, nasolabial folds; chronic relapsing | Clinical |
| Scabies | Severe nocturnal pruritus, burrows in interdigital webs/wrists/genitals; household contacts affected | Mineral oil scraping — mites/eggs/scybala |
Critical differential diagnoses: (1) Secondary syphilis — the most important mimic; can produce papulosquamous rash on trunk, but unlike PR involves palms and soles (~70%), is typically symmetrical, often associated with mucous patches, lymphadenopathy, fever, malaise; ALWAYS check RPR/VDRL in any sexually active patient with truncal papulosquamous rash even if classic for PR. (2) Tinea corporis (especially multifocal) — annular plaques with central clearing; KOH prep of scale shows hyphae; PR lesions also annular but KOH negative. (3) Drug eruption (“pityriasis rosea-like drug reaction”) — caused by ACE inhibitors (captopril classic), beta-blockers, NSAIDs, PPIs, penicillamine, isotretinoin, COVID-19 vaccines, others. Lacks herald patch, often more confluent and pruritic, atypical distribution. Resolves with drug discontinuation. (4) Guttate psoriasis — small papular eruption often after streptococcal infection; thicker scale than PR, may have personal/family history of psoriasis. (5) Nummular eczema — coin-shaped, often very pruritic, less linear arrangement. (6) Pityriasis lichenoides chronica — small reddish-brown papules; chronic course. (7) Mycosis fungoides (early-stage CTCL) — chronic, biopsy if persists >8-12 weeks. Workup: in classic presentations no testing needed; ALWAYS obtain RPR/VDRL if sexual activity history; KOH if uncertain about tinea; skin biopsy if atypical features, prolonged course >3 months, or treatment failure; review medication list for drug etiology. Anti-syphilis testing threshold: low — undiagnosed syphilis is a major public health concern and presents as papulosquamous rash regularly.
S5 · Treatment and Symptom Management
Pityriasis rosea is self-limited in 6–8 weeks (occasionally up to 12 weeks). Treatment is therefore symptomatic, focused on pruritus and reassurance. The 2019 Cochrane systematic review found weak evidence supporting acyclovir and inconclusive evidence for other treatments.
First-line: symptomatic management
| Modality | Regimen | Indication |
|---|---|---|
| Patient education and reassurance | Explain self-limited course (6–8 weeks); not contagious in usual contact; not allergy or fungus | All patients |
| Emollients | Plain petrolatum, ceramide creams BID | All patients — restore barrier, reduce pruritus |
| Mid-potency topical corticosteroid | Triamcinolone 0.1% cream BID × 1–2 weeks or hydrocortisone valerate 0.2% BID | Pruritic or inflammatory lesions; avoid face/groin (use desonide 0.05%) |
| Oral antihistamine — second-generation (non-sedating) | Cetirizine 10 mg PO daily or loratadine 10 mg daily or fexofenadine 180 mg daily | Daytime pruritus |
| Oral antihistamine — first-generation (sedating, for nighttime) | Hydroxyzine 25 mg PO q6h prn or diphenhydramine 25–50 mg at bedtime | Severe pruritus disrupting sleep |
| Oatmeal baths, calamine lotion, menthol/pramoxine lotion | As needed | Adjunctive symptomatic relief |
Second-line for severe or extensive disease
- Oral acyclovir: 800 mg PO 5 times daily × 7 days. Rationale targets HHV-6/HHV-7 reactivation. Multiple small RCTs and a 2019 Cochrane review suggest possible benefit in shortening duration and reducing pruritus, particularly when started within the first week of the eruption. Evidence quality is low to moderate; consider in severe, extensive, or persistent cases. Pediatric dose: 20 mg/kg PO 4 times daily × 7 days (max 800 mg/dose).
- Narrowband UVB (NB-UVB) phototherapy: 5 sessions over 1–2 weeks, starting at 80% of MED. Reduces pruritus and may shorten duration. Useful for extensive disease or cosmetic concern; risk of post-inflammatory hyperpigmentation in dark-skinned patients should be discussed.
- Oral erythromycin: previously suggested but Cochrane review found no significant benefit; not currently recommended.
When to refer to dermatology
S6 · Special Populations and Prognosis
Pregnancy
Several observational studies, most notably from Drago et al., have linked pityriasis rosea in pregnancy with adverse fetal outcomes:
- Miscarriage rate: 13–22% in pregnancies where PR onset occurs before 15 weeks gestation, vs background ~10%.
- Preterm delivery: increased risk in some series.
- Neonatal hypotonia and weak motor activity: described in case series, attributed to HHV-6/HHV-7 transmission.
- Mechanism: maternal HHV-6/HHV-7 viremia may cross the placenta during a vulnerable window.
Management of PR in pregnancy:
- Confirm diagnosis and exclude syphilis (RPR/VDRL).
- Counsel on the observational risk data without alarming the patient (causation is not definitively established and absolute risk remains low).
- Refer to obstetrics for monitoring; serial ultrasound to assess fetal growth.
- Symptomatic treatment with oral antihistamines (loratadine and cetirizine are pregnancy category B; chlorpheniramine has long safety record); topical mid-potency steroids in limited area are acceptable.
- Acyclovir is FDA pregnancy category B and considered safe; consider 400 mg PO TID × 7 days if onset within first trimester, particularly within the first 15 weeks, although evidence is limited.
Pediatric pityriasis rosea
- Less common than in young adults but well-described from age 2 onward.
- Atypical presentations more common in children: inverse PR, vesicular PR, papular PR, facial involvement.
- Often shorter duration (4–6 weeks).
- Pruritus may be more prominent.
- Pediatric dosing: cetirizine 2.5 mg (6 mo–2 yr), 5 mg (2–6 yr), 10 mg (≥6 yr) PO daily; hydroxyzine 0.5 mg/kg PO q6h prn for severe pruritus; topical hydrocortisone 1–2.5% for mild eruption or triamcinolone 0.025% for moderate; pediatric acyclovir 20 mg/kg PO q6h × 7 days for severe cases (max 800 mg/dose).
Pityriasis rosea in immunocompromised patients
HIV-positive patients can present with atypical PR-like eruptions during seroconversion or with antiretroviral therapy initiation. Always test for HIV in atypical or persistent PR. Solid organ transplant recipients and patients on chemotherapy may have more extensive or prolonged PR; managing the underlying immunosuppression takes priority.
Post-inflammatory pigmentation
Post-inflammatory hyperpigmentation (PIH) is common in dark-skinned patients (Fitzpatrick III–VI), occurring at sites of resolved lesions and persisting for weeks to months. Post-inflammatory hypopigmentation is less common. Management: photoprotection (broad-spectrum sunscreen SPF ≥30), and for refractory PIH, consider topical hydroquinone 4% nightly × 8–12 weeks under dermatology supervision.
Prognosis and long-term outlook
- Spontaneous resolution in 6–8 weeks (range 2–12 weeks).
- Recurrence: 2–3% over a lifetime.
- No long-term sequelae aside from transient pigmentary change.
- No association with later autoimmune or malignant conditions.
- Pregnancy outcomes in subsequent pregnancies are generally normal.
Practice Insights: Look for the Herald Patch, Always Rule Out Syphilis, Christmas Tree Confirms Pattern, Watch Pregnancy First Trimester
Herald Patch — The Diagnostic Anchor (Ask About It)
In experienced practice the herald patch identifies PR with high specificity when present. Description: typically a single, well-defined 2-5 cm oval-to-round erythematous plaque with central clearing and a fine, collarette of scale at the periphery (trailing scale pointing inward); usually located on trunk, upper arms, or neck; precedes the generalized eruption by ~1-2 weeks. What experienced practice asks explicitly: “Before this rash spread, did you have a single larger spot — maybe an inch or two across — somewhere on your trunk or upper body, possibly oval-shaped, that you might have thought was ringworm or an insect bite?” Many patients had attributed it to “a bug bite” or “a patch of dry skin” and only recall it when prompted. Atypical PR (without classic herald patch): ~20-30% of cases; or herald patch in unusual location (face, axilla, groin); requires more reliance on subsequent eruption pattern and exclusion of differentials. What experienced practice documents: presence/absence of herald patch, location, dimensions, timing relative to generalized eruption. What experienced practice avoids: dismissing the patient’s earlier “spot” as separate diagnosis when it could be the herald patch; missing herald patch in atypical locations (genital, axilla, oral mucosa — rare but described).
Christmas Tree Pattern — Langer’s Lines
Experienced practice would argue the Christmas tree distribution is highly specific when present. Pattern description: oval lesions arranged with their long axes along Langer’s skin tension lines, creating a pattern resembling drooping branches on the back when patient stands with arms at sides; lesions typically distribute on trunk, neck, upper arms, and upper thighs while sparing face, palms, and soles. Lesion characteristics: smaller secondary lesions are 0.5-2 cm oval salmon-colored to brown patches with fine peripheral scale; central area is finely wrinkled; lesions follow predictable arc patterns. Inverse PR variant: lesions concentrated in axillae, groin, and flexural areas rather than trunk — atypical distribution. Other variants: pediatric PR may have papular morphology rather than oval plaques; vesicular PR with vesicles; purpuric PR; PR-like lesions in COVID-19 era. What experienced practice does: examine back with patient standing arms at sides to optimize Christmas tree visualization; photograph if diagnosis uncertain or for documentation; full skin exam including palms/soles to assess for syphilis. What experienced practice avoids: requiring full Christmas tree pattern before diagnosis (frequently incomplete); missing variant presentations because they don’t fit textbook description.
Rule Out Syphilis — RPR Threshold Is Low
in experienced hands every sexually active patient with truncal papulosquamous rash gets RPR/VDRL, even if PR seems classic. Why: secondary syphilis is the most consequential differential; missed syphilis progresses to tertiary syphilis years later with cardiovascular and neurological manifestations; secondary syphilis is also transmissible — public health implications. Distinguishing features when present: palmar/plantar involvement (~70% of secondary syphilis, almost never in PR — examine palms and soles always); mucous patches in oral cavity and genital region; lymphadenopathy (often substantial generalized adenopathy); systemic symptoms (low-grade fever, malaise, headache) — though both PR and secondary syphilis can have prodrome; non-pruritic in syphilis vs mild-moderate pruritus in PR. RPR/VDRL testing: rapid plasma reagin (RPR) or VDRL with reflex to FTA-ABS or treponemal assay for confirmation; if positive, contact tracing and treatment per CDC STI guidelines. What experienced practice does at first visit: full skin exam including palms/soles, oral mucosa; lymph node exam; history of sexual practices and partners (gentle but explicit); order RPR routinely if any uncertainty or sexual activity. What experienced practice avoids: skipping RPR because patient “doesn’t look like the type” (bias); failing to examine palms/soles; not following up on lab result after initial diagnosis.
Self-Limited Course — Reassurance Over Treatment
Experienced practice would say the natural history is the most important counseling point. Typical course: 6-8 weeks from onset to complete resolution; herald patch may already be fading when generalized eruption appears; new lesions can continue to appear for 2-4 weeks; resolution from center outward; post-inflammatory hyperpigmentation common, especially in darker skin types — fades over months. Treatment for asymptomatic disease: reassurance, expectation-setting, sunlight exposure (often accelerates resolution), bland emollients for dry/scaly areas. For symptomatic pruritus: low- to mid-potency topical corticosteroids (triamcinolone 0.1%) BID to affected areas; oral antihistamines (cetirizine, hydroxyzine) for nocturnal pruritus; tepid baths with colloidal oatmeal. For severe/extensive disease: UVB phototherapy (broadband UVB cleaner skin and faster resolution); oral erythromycin 250-500 mg QID × 14 days (some evidence for faster resolution, particularly if HHV reactivation theory correct); oral acyclovir 800 mg 5×/day × 7 days (case series support, particularly early in course). What experienced practice avoids: aggressive topical steroids without indication; oral corticosteroids (limited evidence, side effects); excessive workup in classic self-limited cases without atypical features.
First-Trimester Pregnancy — Special Caution
Experienced practice would say pregnancy-associated PR deserves special attention. Evidence base: observational studies (Drago et al., others) suggest PR in first trimester is associated with increased risk of spontaneous abortion (13–22% if PR before 15 weeks vs background ~10%); evidence is from small studies and debated, but the signal warrants caution. Mechanism hypothesis: HHV-6/HHV-7 reactivation in maternal blood and placental transfer; viral effect on fetal development. What experienced practice does for pregnant patients with PR: high-risk obstetric consultation; consider acyclovir 800 mg 5×/day for 7 days in first or early second trimester (small evidence base but pregnancy category B); careful obstetric monitoring with serial ultrasounds; explicit informed consent about uncertain evidence base. For second/third trimester PR: less concerning data; symptomatic management with topicals and supportive care typically sufficient. Counseling: explain limitations of evidence; provide written summary; involve maternal-fetal medicine specialist if patient anxious or first-trimester. What experienced practice avoids: dismissing pregnancy concerns (“PR is benign in pregnancy”) when literature suggests caution; aggressive intervention without informed consent given the limited evidence; failing to monitor obstetric outcomes.
Case: Late-20s Female — Apparent PR That Was Secondary Syphilis
A woman in her late 20s presented to primary care with a 2-week truncal rash. She reported a single “ringworm-like spot” on her upper back 10 days before the broader rash appeared. Examination showed: oval salmon-pink to brown patches with peripheral scale on trunk, upper arms, and upper thighs in a distribution suggesting Christmas tree pattern. Initial diagnostic impression: classic pityriasis rosea. Critical complete exam: palmar surfaces showed 4-5 reddish-brown macules bilaterally — not consistent with classic PR. Plantar surfaces showed similar lesions. Generalized small lymphadenopathy was present (axillary and cervical). She acknowledged a non-painful genital ulcer 6 weeks prior that resolved spontaneously (consistent with primary syphilis chancre). Diagnostic shift: ordered RPR and FTA-ABS. RPR titer 1:128; FTA-ABS positive — secondary syphilis confirmed. Treatment: benzathine penicillin G 2.4 million units IM × 1; counseled about Jarisch-Herxheimer reaction; partner notification initiated through public health; HIV and other STI screening (negative). Follow-up: RPR titer monitoring — 1:32 at 6 months, 1:8 at 12 months (fourfold decrease confirms treatment response). Rash resolved over 4-6 weeks. Counterfactual: if PR had been the working diagnosis without RPR check, syphilis would have progressed to latent then potentially tertiary syphilis with cardiovascular or neurological complications years to decades later; partner transmission could have continued during latency.
Protocol Tweaks Seasoned Clinicians Apply (Practice Refinements)
- Ask explicitly about herald patch: “Did you have a single larger spot before the rash spread?” Often missed when only generalized eruption is reported. Document presence/absence and timing.
- RPR/VDRL on every sexually active patient with truncal papulosquamous rash: examine palms, soles, oral mucosa, lymph nodes. Low threshold to test. Missed syphilis is catastrophic.
- Self-limited 6-8 weeks — reassurance + symptomatic Tx: topical corticosteroid + antihistamine for pruritus; UVB or erythromycin or acyclovir for severe; avoid systemic steroids.
- First-trimester pregnancy needs MFM consultation: acyclovir consideration; serial ultrasound monitoring; explicit informed consent given limited evidence; second/third trimester less concerning.
Frequently Asked Questions
- Phototherapy in Dermatology: NB-UVB, PUVA, and Excimer Laser Indications & Protocols
- Androgenetic Alopecia: Pattern Hair Loss Diagnosis, Minoxidil, Finasteride & PRP
- Drug Eruptions: Recognition, Risk Stratification, and Management of Cutaneous Drug Reactions
- Dermatomyositis: Pathognomonic Skin Findings and Diagnostic Workup
- Common Warts and HPV Skin Infection: Cryotherapy, Topical Therapy, and Refractory Management
- Melanoma Diagnosis: ABCDE Criteria, Dermoscopy, Biopsy, and AJCC 8 Staging
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- CDC 2021 Sexually Transmitted Infections Treatment Guidelines (MMWR. Recommendations and Reports · 2021)